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Abstract: Methylphenidate (MPD) is a central nervous system (CNS) stimulant, which belongs 
to the phenethylamine group and is mainly used in the treatment of attention deficit hyperactive 
disorder (ADHD). However, a growing number of young individuals misuse or abuse MPD to 
sustain attention, enhance intellectual capacity and increase memory. Recently, the use of MPD 
as a cognitive enhancement substance has received much attention and raised concerns in the 
literature and academic circles worldwide. The prescribing frequency of the drug has increased 
sharply as consequence of the more accurate diagnosis of the ADHD and the popularity of the 
drug itself due to its beneficial short-term effect. However, careful monitoring is required, because of possible abuse. 
In this review different aspects concerning the use of MPD have been approached. Data showing its abuse among college 
students are given, when the drug is prescribed short term beneficial effects and side effects are provided; moreover 
studies on animal-models suggesting long lasting negative effects on healthy brains are discussed. Finally, emphasis is 
given to the available formulations and pharmacology. 
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1. INTRODUCTION 
 Methylphenidate (MDP) is a central nervous system 
(CNS) stimulant, of the phenethylamine class, available on 
the market with the following trade names: Ritalin, Equasym 
XL, Concerta, Quillivant XR, Methylin, Metadate and 
Focalin. Its street names are the following: Bennies, Black 
Beauties, Cat, Coke, Crank, Crystal, Flake, Ice, Pellets,  
R-Ball, Skippy, Snow, Speed, Uppers, and Vitamin R. The 
drug was first synthesized in 1944 and launched as Ritalin by 
Ciba-Geigy Pharmaceutical Company in 1954. It was 
originally used, after licensed in 1955 by the U.S. Food and 
Drug Administration (FDA), for the treatment of lethargy, 
narcolepsy, chronic fatigue, disorders associated with 
depression and what was then known as hyperactivity [1]. 
However, its most impressive beneficial effect has been the 
decrease of the symptoms noticed in attention deficit 
hyperactivity disorder (ADHD), which is one of the most 
common behavioral disorders in childhood and may persist 
into adulthood [2, 3] found in approximately 3% to 5% of 
the general population of school-age children, occurring 
more frequently in boys [4-6]. Its prevalence may rise up to 
17% when less strict criteria are used [7]. In 1990, when 
diagnosis of the ADHD became more broadly accepted the 
MDP became the drug of choice for the treatment of this  
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disorder with its prescription exceedingly increasing [4, 8-
11]. In general, MPD is safe when used as prescribed and 
produces limited side effects when used orally in therapeutic 
doses [12-15]. Although, MPD’s safety, efficacy and cost 
effectiveness have been documented in many studies [16, 
17] there is still a gap of knowledge regarding its long-term 
effects on brain function and structure and its influence on 
brain development. 
 Historically, in 1937, Charles Bradley reported a positive 
effect of stimulant medication in children with various 
behavior disorders [18]. Many of the children previously 
mentioned would probably be diagnosed with ADHD today 
[19]. Bradley discovered the beneficial effects of stimulants 
on children behavior symptomatically, in his attempt to treat 
their headaches produced after pneumoencephalograms as 
result of a considerable loss of spinal fluid. Benzedrine, “the 
most potent stimulant available at the time” was used by 
Bradley to treat the headaches. Although benzedrine had 
only a tiddley effect on the headaches, it caused an astonishing 
improvement in behavior and school performance in some of 
the children. Subsequent trials of Bradley led to the same 
conclusion i.e. the use of benzedrine improved the school 
performance of approximately half the children and they 
“were more interested in their work and performed it more 
quickly and accurately” [19]. However, his revolutionary 
observations had no influence on practice at the time since 
the assumption that behavioral disorders require psychological 
interventions was predominant [20]. Posterior studies for 
example by Denhoff et al. [21] produced growing interest in 
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stimulant treatment of hyperkinetic children. At present, 
stimulant medication is the most frequently used treatment 
for children with ADHD and MPD is the stimulant of first 
choice, [9, 22] while benzedrine, which was the first 
stimulant used for the same purpose, is no longer in use [8]. 
2. MATERIALS AND METHODS 
 Some databases, from 1957 to 2015, were searched: 
Medline, Cochrane Central, Scopus, Web of Science, 
ScienceDirect, EMBASE and Google Scholar, using the 
following keywords: Methylphenidate, cognitive enhancement, 
ADHD, abuse, long-term effects, Ritalin, Concerta, Metadate, 
Methylin and Focalin. The main key word “Methylphenidate” 
was individually searched in association to each of the 
others. Among the 7305 sources found after the initial 
screening in order to exclude duplicate sources, 134 
references, taking into consideration the aims of the paper, 
were selected.  
3. PHARMACOLOGY AND AVAILABLE FORMULA- 
TIONS 
 ADHD and other related disorders are considered to be 
associated with dopamine and norepinephrine sub-
performance in the brain, particularly in the prefrontal cortex 
(PFC) [23]. As already mentioned, ADHD is a common 
developmental disorder that affects school–age children [24] 
and impairs the functioning of the frontal lobes, specifically 
the PFC, which is responsible for self-regulatory functions, 
including among others motivation, memory and inhibition. 
Executive function (EF) refers to the mental control 
procedures, encompassing cognitive, physical and emotional 
control, that are requested to maintain effective goal-directed 
behavior, which includes problem solving, planning and 
organizing skills [23]. Deficits in EFs have been suggested to 
lead to cognitive difficulties experienced by children with 
ADHD [25, 26]. Deficits in working memory (WM), which 
is a key EF, have been cited in individuals with ADHD [27, 
28]. Moreover, a lot of studies have indicated that WM 
impairments are central to ADHD [29, 30]. 
 Since MPD’s mechanism of action implicates the 
inhibition of catecholamine reuptake, principally as a 
dopamine reuptake inhibitor, the drug is considered efficient 
for the control of the symptomatology of ADHD, which is 
mostly consistent with the dysfunction of the PFC. MPD acts 
by blocking both dopamine and norepinephrine transporters, 
which leads to increased extracellular dopamine and 
norepinephrine concentrations in PFC [31] and dopamine in 
the striatum [32-36]. It has been shown that working 
memory performance is facilitated after a low dose of MPD 
infusion in PFC, whereas infusion of MPD into striatum has 
no reaction on this PFC-dependent cognition task [37], 
suggesting that PFC is a main site for MPD’s therapeutic 
action [38, 39]. In vivo, acute administration of MPD exerts 
excitatory actions on the PFC neurons by an indirect 
activation of alpha2-adrenoceptors and D1 receptors [38, 40-
42], while in vitro, the drug could enhance excitability of 
pyramidal PFC neurons by activating alpha-2 receptors 
located in interneurons [43]. Zhang et al. found that MPD 
facilitates NMDA-receptor mediated excitatory synaptic 
transmission through σ1 receptors via PLC/PKC signaling 
[44]. Evidence also suggests that alpha2A adrenoceptor gene 
is involved with the MPD-induced improvement in ADHD 
[45]. 
 MPD is highly effective in improving the core symptoms 
of ADHD [46]. Pietrzak et al. suggested that MPD improved 
response inhibition, attention control and sustained attention 
in approximately 70% of the studies examined [47]. 
Moreover, WM is improved by MPD through dopaminergic 
transmission facilitation [48]. Although, the most recent 
findings suggest that impairments in visuospatial WM 
(VSWM) is common to individuals with ADHD [29, 49], 
there is a limited number of studies investigating the 
effectiveness of MPD on VSWM in children with ADHD 
[50, 51]. 
 MPD (structure is shown in Fig. 1) can be found on the 
market in various forms under numerous brand names and 
formulations including tablets, capsules, oral suspension 
(liquid syrup) and adhesive-based matrix transdermal system 
(patch). The drug is currently administered either as extended 
[52-54], instant-release or as an osmotically controlled-






Fig. (1). Methylphenidate chemical structure. 
 
 Newer long-acting formulations include an immediate-
release ingredient to ensure the instant onset of action and an 
extended-release ingredient, which continues acting throughout 
the day. Thus, a rapid onset of action can be achieved with 
one dose per day. Different technologies are used for the 
numerous MPD formulations aiming to control the symptoms 
for at least 8 hours and incorporate different proportions of 
instant and extended-release MPD. For instance, Focalin 
XR® and Ritalin LA® use Spheroidal Oral Drug Absorption 
System (SODAS®) technology to supply 50% of the MPD 
dose instantly and 50% as extended release [57]. 
 dl-threo-Methylphenidate exists as two enantiomers,  
l-threo-methylphenidate (l-MPD) and d-threo-methylphenidate 
(d-MPD). d-MPD has been developed as a medicine to  
treat ADHD itself. dl-threo-Methylphenidate undergoes 
enantioselective metabolism in the liver, resulting in 
remarkable variations in the plasma concentrations of its 
isomers, depending on both the formulation administered and 
the route of administration. Plasma d-MPD concentrations 
are higher than those of l-MPD when dl-threo-methylphenidate 
is taken orally. Nevertheless, with the newly developed 
methylphenidate transdermal system (MTS), 'first-pass' 
metabolism is circumvented and consequently, plasma d-
MPD concentrations are consistent with those reached after 
oral administration, but the relative l-MPD concentrations 
are much higher, i.e. 50-60% of those of d-MPD. However, 
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even in this case, it is more possible that the contribution of 
l-MPD to both the adverse effects and effectiveness of the 
racemate is no higher than 5-10% of the total. Transdermal 
drug delivery is considered an effective and safe mean of 
administering MPD to individuals with ADHD [58]. 
 According to Heal and Pierce [36] d-MPD and l-MPD 
have the same pharmacological profile as the parent 
racemate, i.e. acting as catecholamine-selective reuptake 
inhibitors. However, d-MPD is approximately 10 times more 
abundant than l-MPD in this regard. Ritalin LA® contains 
racemic MPD (ie. both d-MPH and l-MPH isomer), like 
most MPD formulation do. Taking into account that when 
the l-MPH is orally administered it is metabolized promptly 
via first pass through hepatic circulation, d-isomer is thought 
to be the main pharmacological contributor in the treatment 
of the disorder. Taking all this into consideration Focalin 
XR® developed a formulation containing only the d-MPH 
isomer. 
 The abilities of these drugs not only to improve the 
cognitive and behavioral impairment but also to modulate 
the common side effects is due to their capacity to potentiate 
noradrenergic and/or dopaminergic function in the central 
and peripheral nervous systems. The authors concluded that 
between the two isomers, d-MPD, which is more abundant 
and potent, contributes more to both the effectiveness and the 
adverse effects, irrespective of the route of administration or 
the formulation of the racemate [36]. 
 MPD’s, formulated as hydrochloride salt, high solubility 
in the fluids of the gastrointestinal tract, leads to rapid and 
extensive absorption from the intestine to the colon [59, 60]. 
Thus, it is more likely that the gastric emptying time is the 
main factor in controlling MPD absorption after immediate-
release intake, whereas for the various controlled-release 
formulations, programmed drug release and the dissolution 
pattern are considered to be the factors which control the 
drug’s absorption. Because of extensive first-pass 
metabolism followed by oral administration, the absolute 
bioavailability is low and variable [61].	  
 Once MPD reaches the systemic circulation, it is 
promptly distributed to various tissues, with a steady-state 
volume of distribution of approximately 2 L/kg [62].  
 MPD is primarily metabolized to the inactive [63] 
metabolite ritalinic acid [59, 64, 65] by deesterification. This 
simple process leads to absolute bioavailability of 11-53% 
[66]. The circulating concentrations of the metabolite 
significantly exceed the concentrations of the parent drug 
[67-70]. Urinary elimination of ritalinic acid accounts for 60-
80% of the dose [59, 64, 65]. 
 Clearance of the drug is also speedy, with little or no 
accumulation of MPD from day to day, even with the 
controlled-release formulations [68]. Nonlinearity, possibly 
related to first-pass metabolism saturation may be noticed at 
higher oral doses [71]. Half-life has been reported to be 2-6 
hours after immediate-release or intravenous dosing with 
most studies reporting an average of 2-3 hours. Longer half-
life is reported for extended-release formulations, but this is 
most probably related to prolonged absorption [72]. 
4. ADVERSE SIDE EFFECTS 
 Although MPD is effective in the majority of children in 
the short term, there is considerable variation in individual 
response to treatment, with a minority not managing 
sufficient symptom control whereas others are unable to 
tolerate the adverse effects of the drug [73-75]. 
 The adverse effects of MPD include among others: pupil 
dilation, [76] loss of hair, depression, anorexia, headaches, 
impairment of libido, insomnia, restlessness, anxiety and 
hypersensitivity [77-80]. Data obtained by Auger et al. [81], 
demonstrate that patients treated with high-dose stimulants, 
used in the treatment of excessive somnolence disorders, 
showed a significant increase of the occurrence of psychosis, 
psychiatric hospitalizations and substance misuse compared 
to the patients treated with standard doses of the same 
stimulants. In addition, anorexia and tachyarrhythmia were 
more common in the high-dose treated group compared to 
controls. Occasionally, stimulant psychosis can occur during 
long-term therapy with MPD. Thus, regular psychiatric 
monitoring of individuals treated with MPD has been 
recommended [82]. 
 Recent large-scale studies by the US FDA suggest that, 
serious adverse cardiovascular events such as sudden death, 
myocardial infarction, and stroke are not associated with the 
medical use of MPD, amphetamine or other customarily 
prescribed ADHD stimulants in children, young adults, and 
adults [83, 84]. On the other hand, some studies suggest a 
small but significant impact of MPD on the cardiovascular 
system including increases in heart rate and blood pressure 
and sudden cardiac death [85, 86]. 
 Aktepe et al. [87], investigated the side effects of MPD 
in ADHD children (n=126). In 55.5% of cases, MPD was 
used alone, whereas in 26.9% of cases, it was used in 
combination with other medications. Side effects were 
recorded in 51.6% of cases and no side effects in 48.4%. 
MPD treatment had to be ceased in only 5.5% of cases. The 
side effects resulting in the cessation of the treatment with 
MPD are as follows: weight loss, irritability, hyperactivity, 
exacerbation of tics and papular rash. The side effects 
reported are shown in Fig. 2. MPD was used at a dose of 10-
20 mg/day in 89.6% of cases.  
 Moreover, MPD has been associated with the risk of long 
lasting and often painful erections, known as priapism. Thus, 
FDA updated patient medication guides and MPD labels to 
provide information about the rare but important risk of 
priapism. If the previously mentioned disorder is not treated 
immediately, it can result in permanent harm to the penis. 
Priapism is more likely to occur in male patients treated with 
atomoxetine than those treated with MPD. However, due to 
limitations in available information, it is not known how 
frequently priapism appears in patients treated with MPD. 
Cases of a prepubertal child and a 14-year-old male who 
developed priapism after therapy with MPD have been 
reported in literature [88, 89]. It is recommended that 
healthcare professionals should inform male patients about 
the symptoms and signs of priapism and emphasize the 
necessity for immediate treatment, since younger males may 
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not recognize the problem or be too embarrassed to tell 
anyone if it happens [90]. 
 Hepatotoxicity is a rare adverse reaction to MPD. The 
literature review indicates some cases of liver failure 
attributed to MPD, that recovered after the treatment 
cessation. However, a recent study reported a liver failure 
case attributed to MPD, where liver transplantation was 
required. The probable mechanism of liver injury was MPD 
direct toxicity to hepatocytes. Thus, the monitoring of liver 
function is highly recommended in these cases [91]. 
5. ABUSE/MISUSE 
 MPD has been broadly used as drug of abuse because of 
its psychostimulant properties. Moreover, MPD has been 
used by college students in order to achieve the so called 
cognitive enhancement (CE) which is defined as the usage 
(by healthy individuals) of psychoactive drugs aiming at 
enhancing cognition which includes among others 
concentration and memory. CE substances commonly used 
can be divided into three groups: 1) over-the-counter, such as 
caffeine tablets, energy drinks etc.; 2) drugs approved for the 
treatment of certain disorders, such as amphetamines and 
MPD and 3) illicit drugs, such as ecstasy and crystal meth 
[92]. According to users’ reports on ‘self-experiments’ 
Internet forums, abusers either grind the commercially 
available tablets into powder and snort it or they convert it 
into liquid form, since the drug is water soluble, making it 
injectable (intravenous administration). Smoking and oral 
administration have also been reported. Moreover as referred 
in the same forum MPD can be abused in combination with 
other drugs, such as cannabis, oxycodone, amphetamines, 
alprazolam, alcohol and others [93]. 
 Unlike other potent stimulants, there is no clandestine 
production of MPD and diverted pharmaceutical products 
are the only source for abuse purposes. MPD is obtained 
from fraudulent prescriptions, pharmacy theft, doctor 
shopping, and from friends or associates who have obtained 
the drug through a prescription [94]. 
 The potentiality of abuse of MPD was considered in  
the early 1960s in a case report of a patient who was taking 
125 tablets of MPD per day [95]. Reports of oral MPD  
abuse including reports of MPD paranoia [96], hallucinations 
[96, 97], delusional disorder [98] and euphoria [99], appeared 
later in the literature. Intravenous abuse of MPD related  
to psychosis was indicated in 1963 and subsequently 
intravenous abuse was reported in several studies in the  
early 1970s [96, 97, 100]. Afterward, a study depicted the 
intravenous abuse patterns, mortality, and morbidity related 
to MPD [101]. 
 Studies on animals for evaluation of the long-term effects 
of abuse resulted in ambiguous outcomes; negative effects 
like the ones of methamphetamine in low doses and no effect 
in high doses. Additional studies to evaluate potential 
 
Fig. (2). Adverse side effects of Methylphenidate reported by Aktepe et al. [87]. 
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neurotoxicity under such conditions is necessary. It has been 
proved that, the abuse of MPD, when in rare cases 
intravenously administered can even produce dopaminergic 
fibers maturation impairment in subcortical brain areas 
[102]. 
 Many surveys have been conducted suggesting wide 
abuse of the drug as a cognitive enhancer among healthy 
college students. However, it is hard to define the actual 
trend of abuse [103]. According to Teter et al., who 
conducted a research to investigate the motives, prevalence 
and routes of administration of illicitly used prescription 
stimulants among college students, 24.5% of the 269 
students who declared past-year illicit use of prescription 
stimulants, reported MPD use. In the same survey, it was 
found that the motives for illicit use of prescription 
stimulants are the following: to assist with concentration, 
help study, heighten alertness, get high and experimentation. 
Although most users reported oral administration, a 
significant percentage (38%) of users reported intranasal 
administration [104]. 
 Another study, reported that 2.3% of high school seniors 
declared past-year use of Ritalin, while 1.9% used 
methamphetamine [105]. A 2000 study, conducted within a 
liberal art college stated that more than 16% of the students 
who participated had tried MPD recreationally and 
approximately 13% had administrated the substance intranasally 
[106].  
 As reported by the U.S. Department of Health and 
Human Services, in Monitoring the Future National Survey 
Results on Drug Use, 1975-2006 [107], the use of MPD 
among young adults and college students in 2006 was 2.6% 
and 3.9%, respectively. A slight decrease in the use of MPD 
in both groups from 2002 to 2006 was also noted. However, 
compared to the trend of use of other phenethylamines 
commonly abused, such as amphetamines, MPD is less 
commonly abused by both categories.  
 A large study carried out at the University of Michigan; 
found that approximately 3% of the students (out of 2250 
students who completed the survey) had declared past year 
illicit use of the drug. No significant differences between 
males and females percentages of misuse/abuse were found. 
In addition, an association between MPD misuse and use of 
alcohol and drugs was found. In particular, MPD misusers 
were considerably more likely to use drugs and alcohol 
[108]. 
 According to White et al. [109] 16% of students of a 
northeastern US university have misused or abused stimulant 
medications. Of this category, 96% of those specified a 
medication, reported Ritalin as their stimulant of choice. 
More than 50% of the students misusing the drug, reported 
administration of the drug 2-3 times per year, 34% 1-2 times 
per month, while 15.5% of the misusers take the drug 2-3 
times per week. Similar use patterns were reported by the 
two sexes. Reducing hyperactivity, improving attention and 
improving grades were the reasons which lead to misuse or 
abuse of the drug according to the participants. 
 When MPD is intranasally abused similar effects to 
intranasal use of crack cocaine and amphetamines are 
produced [110, 111]. Doses as high as 200mg have been 
reported for intranasal MPD abuse and 40mg-1000mg for 
intravenous abuse [4, 111, 112]. 
 To sum up, comparative analysis is not recommended 
since the methodology used differs from study to study. 
However, data obtained suggest broad abuse/misuse of MPD 
as cognitive enhancer among college students, teenagers and 
young adults [113-115]. Table 1 summarizes the outcomes 
of studies conducted to determine the prevalence of MPD’s 
abuse. 
6. LONG-TERM EFFECTS OF MPD ON THE BRAIN 
 Several studies, involving both animals, mostly rats, and 
humans have been conducted in order to assess the possible 
enhanced cognitive effects of MPD on the normal brain 
[116-118]. It has been reported that high doses (5–10 mg/kg) 
when intraperitoneally administered in rats increase the 
locomotor activity and impair both performance and 
attention. On the other hand, improvement of the cognitive 
performance and reduced motor activity was noted after  
rats were intraperitoneally administered a low dose (0.5–2 
mg/kg) of the drug. Moreover, the administration of even 
lower doses (0.25–1 mg/kg) of MPD in healthy rats heightens 
the attention skills without influencing motor activity [119]. 
 MPD improves the performance of prefrontal cortex 
tasks in both “normal” college students [120] and in patients 
diagnosed with ADHD [121].  
 Since MPD is most commonly prescribed to children and 
adolescents with ADHD at a moment of crucial importance 
for the adolescent because of the development and the 
maturation of the brain, it is thought that drug exposure at 
Table 1. Prevalence of MPD’s abuse and common routes of administration when abused. 
Author Type of Survey Percentage of Individuals Used MPD Routes of Administration 
Teter et al. [104] Web-based 24,5% out of 269 past-year illicit users of prescription stimulants Oral, intranasal 
Babcock and  
Byrne [106] 
Self -reported survey  
(10 yes-and-no questions) 
16.6% out of 283 students  12.7% intranasal 
Teter et al. [108] Internet survey 3% out of 2250 students reported past-year illicit use   
White et al. [109] Internet survey 16% reported abuse/misuse of stimulant medication. 96% of 
those reported Ritalin as the stimulant of choice  
Orally, 40% intranasal 
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this period of life could result in lasting alterations that will 
persist into the adulthood. Lee et al. investigated the effects 
of the repeated drug administration on the locomotor diurnal 
rhythm activity patterns of female Sprague-Dawley (SD) rats 
during adolescence. The experiment involved 31 rats divided 
into the following groups: control, 0.6 mg/kg, 2.5 mg/kg, and 
10 mg/kg MPD group. Saline was injected to all groups on 
the first day of experiment, whereas on days 2-7 rats were 
administered with either saline, 0.6 mg/kg, 2.5 mg/kg, or 10 
mg/kg of MPD. A washout period followed (i.e. Days 8-10). 
The same dose used on days 2-7 was injected again on day 
11 to the four groups, respectively. The obtained data 
illustrated that repeated administrations of both 2.5 mg/kg 
and 10 mg/kg of the drug could alter the locomotor diurnal 
rhythm patterns, suggesting that the previously mentioned 
doses exert long-term effects [122]. 
 The cellular mechanisms of action of MPD and its 
eventual effect on prefrontal cortical circuitry are not fully 
established, in particular within the developing brain system. 
Urban  et al. [123], involve in their experiments both adult 
SD rats and Juvenile (postnatal day [PD] 15), that were 
administered with either saline or MPD. Both neuronal 
excitability and synaptic transmission in pyramidal neurons 
of prefrontal cortex were examined. Moreover, recovery 
from the drug treatment was tested 1, 5 and 10 weeks after 
the last administration of the drug. 
 It was concluded, that either chronic treatment or a single 
dose of 1 mg/kg intraperitoneal MPD, could generate 
considerable depressive effects on pyramidal neurons in 
juvenile rat prefrontal cortex. Doses of 0.03 to 0.3 mg/kg 
also generated depressive effects in juvenile rats, in a linear 
dose-dependent way. Function recovery achieved within 1 
week from chronic 1 mg/kg treatment, while depression of 
prefrontal neurons noticed on rats chronically treated with 3 
and 9 mg/kg lasted 10 weeks and beyond. The obtained data 
suggest that the prefrontal cortex of the juvenile is 
supersensitive to the drug and the acceptable therapeutic 
range for adults is overestimated, since the chronic treatment 
with 1 mg/kg MPD is well correlated with the acceptable 
therapeutic range for adults. In general, juvenile treatment 
with MPD can produce long-lasting and potentially 
permanent changes to excitatory neuron function in the 
prefrontal cortex of juvenile rats [123]. 
 Both meta-analyses and systematic reviews of magnetic 
resonance imaging studies suggest that long-term treatment 
with ADHD stimulants (particularly, MPD and amphetamine) 
reduces abnormalities in brain function and structure found 
in individuals with ADHD [124-126]. Furthermore, both the 
efficacy and the safety of long-term use of ADHD stimulants 
for subjects with ADHD have been established [127]. 
Specifically, the continual treatment efficacy and safety of 
both MPD and amphetamine have been evidenced in 
controlled drug trials with duration of several years [127]. 
 Rats with ADHD-like behavior were employed in animal 
studies aiming to evaluate the safety of MPD on the 
developing brain. It was noted that both psychomotor 
impairments and liturgical and structural parameters of 
dopaminergic system were improved with treatment. 
Nevertheless, MPD produced long lasting alterations to the 
dopaminergic system of healthy control animals. Moreover, 
it was shown that rats treated with MPD grew up to be more 
emotional and stressed [102].  
 Bolaños et al. [128] observed that animals treated with 
MPD showed increased anxiety-like behavior, were 
considerably more sensitive to stressful situations, and had 
enhanced plasma levels of corticosterone, compared to 
controls. However, for the latest study, healthy rats were 
used thus remaining unclear whether MPD could cause 
adverse emotional effects on ADHD animal models [128]. 
7. CONCLUSIONS 
 Data suggest that MPD is a drug of great value that 
nicely fits the pharmacological demands to control dopamine 
dysfunctions in ADHD. However, long lasting alterations  
to the dopaminergic system in normal control animals 
suggest that if a child is misdiagnosed with ADHD he or she 
may be at risk of long lasting unfavorable effects in brain 
development. Thus, careful clinical diagnosis and assessment 
of ADHD symptomatology is required to assure that the drug 
is only prescribed to children with comprehensible ADHD 
symptomatology. Data obtained from animal studies 
illustrate that under the latest conditions MPD is supportive 
for the related behavior and brain development in children 
with ADHD. It is worth pointing out that medical 
malpractice suits, charging physicians with negligent 
misdiagnosis of ADHD and failure to obtain sufficient 
informed consent for the use of stimulants and inadequate 
information on side effects have been raised [129].  
 In addition, clinicians should be very attentive 
concerning the prescribing of dosages higher than the 
maximum guidelines since the latter could result in undesired 
effects. Moreover, due to the numerous formulations 
commercially available, clinicians should be very cautious in 
choosing the most suitable one, taking into account the 
patients’ response to the drug and the different treatment 
needs of each individual. In general, a tailored approach is 
required in order to optimize the treatment of ADHD 
symptoms.  
 Summing up, the wealth of both human and animal data 
of MPD indicates the great significance of the drug, which 
has to be carefully handled in the right way. However, it is 
extremely difficult to compare the studies investigating long 
term effects because of the heterogeneity in data and duration 
which suggests the necessity of systematic monitoring of 
long-term safety of the drug [130]. 
 Nevertheless, the use of MPD and other stimulants for 
the treatment of ADHD symptoms has been controversial 
[131, 132]. One such criticism is the prescription of 
psychostimulants medication to children in order to reduce 
ADHD symptoms [133]. The claim that MPD acts as a 
gateway drug has been discredited by multiple sources, 
according to which MPD rarely leads to addiction or abuse 
when taken appropriately as treatment for ADHD.  
 Data obtained from numerous studies (comparative 
analysis is not recommended, though) suggest broad abuse/ 
misuse of MPD as cognitive enhancer among college 
students, teenagers and young adults [134]. Results obtained 
From Clinical Application to Cognitive Enhancement Current Neuropharmacology, 2016, Vol. 14, No. 1    23 
from studies concerning the effects of the stimulant on 
healthy individuals suggest its abuse is a concern on college 
campuses.  
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